USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
Israeli company NeoTX, a biotech firm with a selective t-cell redirection (STR) platform for developing targeted anticancer immunotherapies, has closed a $45 million Series C financing. 19 February 2020
Belgian bioprocessing provider Univercells has received an injection of 50 million euros from Gamma Biosciences, a new investment platform supported by private equity giant KKR that is focused on technologies for the production of advanced biologic therapies including gene and cell therapies. 19 February 2020
CANbridge Pharmaceuticals has raised $98 million in a series D financing round. General Atlantic and WuXi AppTec led the round, and both have the option to invest up to $10 million extra, if certain conditions are met. 18 February 2020
Government-funded non-profit CARB-X has taken a punt on another company that could help to tackle the emerging antimicrobial resistance crisis. 18 February 2020
French pharma major Sanofi has sought to remove and replace members of the board of Medivation as it resorts to a hostile takeover of the USA-based biotech. 7 February 2020
A new biotech dubbed Anteros Pharmaceuticals has been launched by the drug development accelerator BioMotiv, together with Bristol-Myers Squibb (NYSE: BMY). 4 February 2020
Venture capital firm Arix Bioscience has founded a new biotech, Quench Bio, aimed at developing candidates which inhibit the protein Gasdermin D, a target at the core of multiple inflammatory cell death pathways. 27 January 2020
A report from the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveals robust levels of investment in the UK biotech sector, indicating that companies raised £1.3 billion ($1.7 billion) in 2019. 22 January 2020
US CRISPR gene-editing firm Emendo Biotherapeutics has announced a Series B $61 million investment led by Japanese biotech AnGes, reflecting its strategic interest in partnering with Emendo and increasing its stake in the company to 32%. 18 January 2020
An Expert View column on the need for bosses in the life sciences to understand financing trends from David Diamond, managing director of CBIZ MHM, an accounting and
professional services provider, 14 January 2020
Dutch specialty pharma Pharming Group has announced the placement of 125 million euros ($139 million) of senior unsecured convertible bonds due 2025. 14 January 2020
Swiss biotech NBE-Therapeutics has closed a $22 million Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group, along with participation from all private shareholders. 10 January 2020
US hematopoietic cell transplant therapies focussed biotech Jasper Therapeutics has expanded its Series A financing with an additional investment of $14.1 million led by Roche Venture Fund and with participation from other investors, bringing the total company financing to more than $50 million to date. 10 January 2020
UK-based Avacta Group and Korean pharma Daewoong Pharmaceutical are to form a joint venture (JV) aimed at developing cell and gene therapies incorporating the Cambridge-based company’s Affimer proteins. 8 January 2020
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news